Overview

Palbociclib's three-weeks-on, one-week-off dosing creates predictable, recurring demand, making supply continuity and validated cold-chain handling the priorities for distributors. Buyers should secure a GMP-certified source capable of steady 21-tablet pack deliveries without interruption to the treatment calendar. The 125 mg tablet is the standard starting strength, so forecasting is straightforward once the treated population is known. For B2B sourcing, documentation and delivery reliability outweigh small unit-price differences. A stable chain is the real product feature.

How It Works

Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6, which partner with cyclin D to push cells through the G1 restriction point. By blocking CDK4/6 it prevents retinoblastoma protein phosphorylation, arresting the cell cycle in G1 and halting proliferation of hormone-receptor-positive tumor cells. Because the effect is cell-cycle specific rather than directly cytotoxic, normal rapidly dividing tissues recover during the planned off-week. This mechanism is why the intermittent schedule both preserves activity and limits bone-marrow suppression, and why uninterrupted supply matters for the rhythm.

Indications

Palbociclib is indicated for HR-positive, HER2-negative advanced or metastatic breast cancer, combined with an aromatase inhibitor in first line or with fulvestrant in later lines. Selection follows hormone-receptor status, not a mutation. It is also used in certain metastatic combinations per label. Therapy runs in repeating 28-day cycles while benefit and neutrophil counts are maintained, making the off-week a scheduled, not skipped, part of treatment.

Dosage & Administration

The starting oral dose is 125 mg once daily for 21 consecutive days, followed by 7 days off, repeated in 28-day cycles, with food. Capsules or tablets are swallowed whole. Dose reductions or holds follow rules for neutropenia. The 21-tablet pack matches the active segment exactly, so each new cycle begins with a fresh pack; procurement should align deliveries to cycle starts to avoid treatment gaps.

Storage & Sourcing

Store 125 mg tablets at 2–8 °C in the original blister, protected from light and moisture; do not freeze. Maintain a documented refrigerated chain and verify batch, expiry, and seals on receipt. Rotate by earliest expiry. Because cycles repeat indefinitely, contract recurring shipments and keep GMP and COA files current for audit and uninterrupted dispensing.

FAQ

Q: What supply schedule suits palbociclib's 21/7 dosing cycle?

A: A 21-tablet pack covers the active three weeks, so deliveries timed to each 28-day cycle start prevent gaps; recurring contracted shipments best match the indefinite repeating schedule.

Q: What should buyers verify in a palbociclib GMP certificate?

A: Confirm the manufacturing site, batch number, and GMP scope match the carton, and that the certificate issuer is recognized by the importing regulator before stocking.

Q: Are there cold-chain risks specific to CDK4/6 inhibitor tablets?

A: The main risk is excursion above 8 °C during transit or clinic storage, which can reduce potency; logged packaging and receipt inspection mitigate it.

Q: How is palbociclib typically bundled for hospital tenders?

A: Tenders usually bundle the 21-tablet packs in cycle-quantity lots alongside the partner endocrine agent, with GMP and COA documentation included per batch.